Skip to content

It is a requirement within the EU that all investigational and medicinal products manufactured or imported by organisations holding a MA IMP, have a Qualified Person (QP) to approve and release each batch of IMP for usage in clinical trials.

At Sharp we offer well-established QP services, helping to streamline your product’s journey to trial and market in the EU, as well as giving you and your customers the confidence that your products have been manufactured to the very highest standards.

So what exactly is a Qualified Person?

It’s someone who’s gained personal knowledge of the quality systems used at the manufacturing site, usually through an EU Good Manufacturing Practice Audit. QPs are assigned projects according to their specialist expertise and have personal and legal responsibility as defined by the EU Clinical Trial Directive (2001/20/EC).

Once a satisfactory audit is complete, your Sharp QP will issue a declaration that you can use to submit your Clinical Trial Authorisation (CTA). We can then work with you to manage the storage and distribution of your clinical trial supplies to your testing sites.

Related Resources

Sharp has received Investigational Medicinal Product (IMP) & Wholesale Distribution Authorisation (WDA) licensing approvals to support clinical activities from its facility in The Netherlands.
https://t.co/ap7MUc5Ev5
#clinicalservices #clinicalsupplychain #Brexit

Great to meet new and familiar faces at Pharma & Device Packaging & Labelling Europe 2019 today in Munich. Connect with Scott Forde to learn more about our state of the art facility in Rhymney. @ArenaIntPharma https://t.co/dxRZUgmZVS

#pharma #medicaldevices #clinicaltrials

Are you attending Clinical Innovation Partnerships in Berlin next month? Connect with the Sharp team to learn more about our high-speed bottling capabilities. https://t.co/iUbRiX2S68

#clinicaltrials #clinicaltrial #clinicalresearch #clinicaloperations #pharma